"Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in Bagamoyo District, Tanzania"
Status:
Completed
Trial end date:
2018-02-17
Target enrollment:
Participant gender:
Summary
This clinical trial evaluates the advantage of prolonging the therapeutic life span of
Artemether-lumefantrine from 3 days to 6 days, and addition of single low dose of Primaquine
0.25mg/kg. The study will have two arms, one that will receive standard treatment of
uncomplicated malaria with Artemether-lumefantrine, and the other arm will receive the
prolonged dose of 6 days together with single low dose primaquine. This approach is expected
to provide strategies for malaria control in an era of imminent Plasmodium falciparum
resistance.
Phase:
Phase 4
Details
Lead Sponsor:
Muhimbili University of Health and Allied Sciences
Collaborators:
Karolinska Institutet The University of Western Australia Uppsala University